These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27268272)

  • 1. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.
    Raisch DW; Rafi JA; Chen C; Bennett CL
    Expert Opin Drug Saf; 2016 Aug; 15(8):1003-11. PubMed ID: 27268272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).
    Schmedt N; Andersohn F; Garbe E
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1216-20. PubMed ID: 22821419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database.
    Colin O; Favrelière S; Quillet A; Neau JP; Houeto JL; Lafay-Chebassier C; Pérault-Pochat MC;
    Fundam Clin Pharmacol; 2017 Apr; 31(2):237-244. PubMed ID: 27736027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Induced Progressive Multifocal Leukoencephalopathy: A Comprehensive Analysis of the WHO Adverse Drug Reaction Database.
    Melis M; Biagi C; Småbrekke L; Nonino F; Buccellato E; Donati M; Vaccheri A; Motola D
    CNS Drugs; 2015; 29(10):879-91. PubMed ID: 26507833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive multifocal leukoencephalopathy analyzed using the Japanese Adverse Drug Event Report database.
    Sakurai S; Maezawa M; Nakao S; Hirofuji S; Miyasaka K; Yamashita M; Matsui K; Nishida S; Kobayashi R; Iguchi K; Hayashi Y; Suzuki A; Nakamura M
    J Neurol Sci; 2023 Dec; 455():122789. PubMed ID: 37984106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
    Wittayanukorn S; Qian J; Johnson BS; Hansen RA
    J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.
    Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Hidalgo-Simon A; Egberts AC; Leufkens HG; De Bruin ML
    Clin Pharmacol Ther; 2015 Nov; 98(5):542-50. PubMed ID: 26347128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.
    Piccinni C; Sacripanti C; Poluzzi E; Motola D; Magro L; Moretti U; Conforti A; Montanaro N
    Eur J Clin Pharmacol; 2010 Feb; 66(2):199-206. PubMed ID: 19838692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.
    Kothary N; Diak IL; Brinker A; Bezabeh S; Avigan M; Dal Pan G
    J Am Acad Dermatol; 2011 Sep; 65(3):546-551. PubMed ID: 21514689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
    Carson KR; Evens AM; Richey EA; Habermann TM; Focosi D; Seymour JF; Laubach J; Bawn SD; Gordon LI; Winter JN; Furman RR; Vose JM; Zelenetz AD; Mamtani R; Raisch DW; Dorshimer GW; Rosen ST; Muro K; Gottardi-Littell NR; Talley RL; Sartor O; Green D; Major EO; Bennett CL
    Blood; 2009 May; 113(20):4834-40. PubMed ID: 19264918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
    Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
    Molloy ES; Calabrese LH
    Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
    Rindi LV; Zaçe D; Braccialarghe N; Massa B; Barchi V; Iannazzo R; Fato I; De Maria F; Kontogiannis D; Malagnino V; Sarmati L; Iannetta M
    Drug Saf; 2024 Apr; 47(4):333-354. PubMed ID: 38321317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of temozolomide with progressive multifocal leukoencephalopathy: a disproportionality analysis integrated with network pharmacology.
    Bhati V; Kumar A; Lather V; Sharma R; Pandita D
    Expert Opin Drug Saf; 2024 May; 23(5):649-658. PubMed ID: 37915230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
    Berger JR; Malik V; Lacey S; Brunetta P; Lehane PB
    J Neurovirol; 2018 Jun; 24(3):323-331. PubMed ID: 29508305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive Multifocal Leukoencephalopathy Among Ibrutinib Treatment In Chronic Lymphocytic Leukemia.
    Çetintepe T; Gediz F; Akyar I; Çetintepe L; Koç AM
    J Oncol Pharm Pract; 2022 Jul; 28(5):1249-1253. PubMed ID: 35037793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of progressive multifocal leukoencephalopathy in patients without HIV.
    Amend KL; Turnbull B; Foskett N; Napalkov P; Kurth T; Seeger J
    Neurology; 2010 Oct; 75(15):1326-32. PubMed ID: 20938025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: A case report and literature review.
    Al-Tawfiq JA; Banda RW; Daabil RA; Dawamneh MF
    J Infect Public Health; 2015; 8(5):493-7. PubMed ID: 25666327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy.
    Hsiehchen D; Arasaratnam R; Raj K; Froehlich T; Anderson L
    Oncology; 2018; 95(5):319-322. PubMed ID: 30045034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
    Faulkner M
    Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.